Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration-Reference-Cited by-同舟云学术

Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration

Published:2022-06 Issue:6 Volume:11 Page:964-974
ISSN:2218-6751
Container-title:Translational Lung Cancer Research
language:
Short-container-title:Transl Lung Cancer Res

Author:

Gao Guanghui,Ni Jian,Wang Yina,Ren Shengxiang,Liu Zhihua,Chen Gongyan,Gu Kangsheng,Zang Aimin,Zhao Jun,Guo Renhua,He Jianxing,Lin Xiaoyan,Pan Yueyin,Ma Zhiyong,Wang Zhehai,Fan Min,Liu Yunpeng,Cang Shundong,Yang Xinfeng,Li Weixia,Wang Quanren,Zhou Caicun

Publisher

AME Publishing Company

Subject

Oncology

Link

https://tlcr.amegroups.com/article/download/65194/pdf

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers;Cancer Treatment Reviews;2024-04

2. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer;Frontiers in Immunology;2023-12-06

3. Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases;Translational Lung Cancer Research;2023-11

4. Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer;Frontiers in Immunology;2023-10-16